23andMe Genetic Data Acquisition has sparked a significant conversation in the realm of consumer genetic testing, especially following Regeneron Pharmaceuticals’ recent purchase of the beleaguered company.Once valued at an astonishing $6 billion and famous for making DNA testing accessible, 23andMe’s journey has taken a dramatic turn with its filing for bankruptcy.